Browse the evidence

81.51% of the cohort lost a 'meaningful' amount of weight (5% or more).

A high percentage of participants achieved significant weight loss, indicating the program's effectiveness.

Exercise is a first-line prevention and intervention strategy for type 2 diabetes.

Practitioners should prioritize exercise as a key component in diabetes prevention and treatment.

The 'food labels & real-time feedback' and 'ordering' strategies had significantly positive main effects on overall diet quality of the shopping basket.

Implementing food labels with real-time feedback and ordering by nutritional quality can significantly enhance diet quality in online grocery shopping.

Combining 'food labels & real-time feedback' and 'ordering' interventions is more effective than using either intervention alone.

Using a combination of food labels with real-time feedback and ordering can significantly enhance diet quality in online grocery shopping.

The use of long‐acting incretin‐based therapies, such as semaglutide, has increased due to their benefits for glycemic control in diabetes, cardiovascular risk reduction, and weight management.

Clinicians should consider the benefits of semaglutide for patients with diabetes and weight management needs.

Retatrutide exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM).

Retatrutide may be an effective treatment option for managing HbA1c and weight in T2DM patients.

In non-T2DM individuals, retatrutide produced substantial weight loss and improved glucose levels.

Retatrutide may also benefit non-T2DM individuals seeking weight loss and improved glucose control.

Behavioral interventions and pharmacological therapies may be effective strategies for weight management in PWH.

Integrating behavioral and pharmacological approaches may enhance weight management efforts in PWH.

New glucose-lowering drugs, such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, have been confirmed to reduce weight and preserve kidney function.

Clinicians may consider these new drugs as effective treatment options for managing ORG.

Addition of glucagon receptor agonism enhances weight loss, reduces liver fat, and ameliorates dyslipidemia.

Practitioners should consider glucagon receptor agonists for their potential benefits in weight loss and metabolic health.

SGLT-2 inhibitors and GLP-1 receptor agonists (GLP-1RAs) lead to a decline in body weight ranging from 1.5 to 5 kg.

Practitioners can consider SGLT-2 inhibitors and GLP-1RAs as effective options for weight loss in patients.

Liraglutide and semaglutide may provide benefits for weight loss and glycaemic control in people living with HIV.

Practitioners may consider liraglutide and semaglutide for weight management in HIV patients, particularly those with diabetes.

The STEP HFpEF and SELECT trials demonstrated that semaglutide improves clinical outcomes in obese HFpEF patients and reduces cardiovascular and heart failure events in non-diabetic obese patients.

Practitioners should consider semaglutide as a treatment option for improving outcomes in obese HFpEF patients.

Obesity is a major risk factor for the development and progression of type 2 diabetes.

Addressing obesity is crucial for managing type 2 diabetes.

A healthy lifestyle is essential for the long-term success of any therapeutic intervention for obesity.

Encouraging lifestyle changes is vital for effective obesity treatment.

Practical recommendations for weight management should include supportive communication and shared decision-making.

Incorporating communication strategies can enhance weight management efforts.

The use of chains during resistance training (CRT) resulted in a 28% improvement in bench press 1RM compared to a 19% improvement with traditional resistance training (TRT).

Incorporating chains into resistance training may enhance strength gains more effectively than traditional methods.

Both CRT and TRT groups showed improvements in strength compared to the non-exercise control group (CG).

Both CRT and TRT are effective for improving strength in recreationally-trained individuals.

CRT led to an 8% improvement in back squat endurance, while TRT only showed a 2% improvement.

Using chains in resistance training may enhance muscular endurance more than traditional methods.

GLP-1RA medications are effective in achieving optimal glucose control and reducing all-cause death, cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, and end-stage kidney disease in individuals with type 1 and type 2 diabetes.

GLP-1RA medications can be considered for improving glucose control and reducing serious health risks in diabetic patients.

NuSH-based therapies, including semaglutide and tirzepatide, are highly effective for the treatment of overweight (BMI >27 kg·m−2 with a health condition) and obesity (BMI >30 kg·m−2), with average weight loss exceeding that achieved with lifestyle modification alone.

Healthcare providers should consider prescribing NuSH-based therapies for patients struggling with overweight and obesity.

Chronic use of NuSH-based therapies may improve weight loss in patients who have not responded optimally or have experienced weight recurrence after metabolic/bariatric surgery.

Consider NuSH-based therapies for patients who have struggled with weight loss after surgery.

Physical activity should be promoted as a foundational component of care for patients receiving NuSH-based treatments for obesity.

Encourage physical activity as part of a comprehensive treatment plan for obesity.

The FDA has approved GLP-1R agonists, liraglutide and semaglutide, for the management of obesity.

Practitioners can consider GLP-1R agonists as viable pharmacological options for obesity management.